Citation

Sahraei Z, Eshraghi A, Eslami N, Mehdizadeh M. Am. J. Ther. 2015; 23(6): e1579-e1585.

Affiliation

1Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran;2Department of Pharmacology, Faculty of Pharmacy, Lorestan University of Medical Sciences, Khorramabad, Iran;3Department of Statistics, Faculty of Mathematical Sciences, Shahid Beheshti University, Tehran, Iran; and4Department of Statistics, Faculty of Mathematical Sciences, Shahid Beheshti University, Evin Tehran, Iran.

Copyright

(Copyright © 2015, Lippincott Williams and Wilkins)

DOI

10.1097/MJT.0000000000000192

PMID

26938753

Abstract

Renal transplantation is the treatment of choice for many patients with end-stage renal disease. Because there is little information about depression after kidney transplantation, we investigated frequency and determinant factors of depression and also its association with interleukin (IL)-18. Kidney transplant recipients were investigated between January 2011 and February 2013. Depression was assessed using the Beck Depression Inventory (BDI, BDI-II). We investigated the relationship between 1-year posttransplantation depression and all-cause mortality, acute kidney injury, and serum creatinine 1, 3, and 12 months after transplantation. Furthermore, the association of depression with IL-18 biomarker was recorded 1 year after transplantation. A total of 74 patients (age: 37.06 ± 16.2 years; 59.5% male) were enrolled in this study 1 year after transplantation. Nineteen (25.6%), 2 (2.7%), and 1 (1.3%) of them experienced mild, moderate, and severe depression, respectively. IL-18 biomarker (independent variable) was significantly associated with depression 1 year after transplantation. Our data suggested that IL-18 level increased significantly in renal transplant patients with depression.

Language: en